[
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
[og_img]
https://www.investing.com/news/press-releases/sutro-biopharma-presents-data-from-doseoptimization-portion-of-refrimeo1-trial-in-patients-with-platinum-resistant-ovarian-cancer-at-sgo-2025-93CH-3930796
Investing.com
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Related articles